Accepted Manuscript

Title: The isothiocyanate produced from Glucomoringin inhibits NF- κ B and reduces myeloma growth in nude mice *in vivo*

Authors: Dario Brunelli, Michele Tavecchio, Cristiano Falcioni, Roberta Frapolli, Eugenio Erba, Renato Iori, Patrick Rollin, Jessica Barillari, Carla Manzotti, Paolo Morazzoni, Maurizio D'Incalci

PII: S0006-2952(09)01066-1
DOI: doi:10.1016/j.bcp.2009.12.008
Reference: BCP 10405

To appear in: *BCP*

Received date: 20-10-2009
Revised date: 4-12-2009
Accepted date: 7-12-2009

Please cite this article as: Brunelli D, Tavecchio M, Falcioni C, Frapolli R, Erba E, Iori R, Rollin P, Barillari J, Manzotti C, Morazzoni P, D'Incalci M, The isothiocyanate produced from Glucomoringin inhibits NF- κ B and reduces myeloma growth in nude mice *in vivo*, *Biochemical Pharmacology* (2008), doi:10.1016/j.bcp.2009.12.008

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

The isothiocyanate produced from Glucomoringin inhibits NF- κ B and reduces myeloma growth in nude mice *in vivo*

Dario Brunelli^{a,*}, Michele Tavecchio^a, Cristiano Falcioni^a, Roberta Frapolli^a, Eugenio Erba^a, Renato Iori^b, Patrick Rollin^c, Jessica Barillari^b, Carla Manzotti^d, Paolo Morazzoni^d, and Maurizio D'Incalci^a

^(a)Laboratory of Cancer Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa 19, 20156 Milano, Italy

^(b)Agricultural Research Council, Research Center for Industrial Crops (CRA-CIN), Via di Corticella 133, 40129 Bologna, Italy

^(c) Institut de Chimie Organique et Analytique UMR-CNRS 6005, Université d'Orléans, B.P. 6759, F-45067 Orleans Cedex 2, France

^(d) Indena S.p.A., Viale Ortles 12, 20139 Milano, Italy.

^(*)Corresponding author: Brunelli Dario, Via La Masa 19, 20156 Milano, Italy, Tel: +39 02 39014239; Fax: +39 02 39014734; E-mail: brunelli@marionegri.it

ABSTRACT

Glucosinolates (GLs), natural compounds extracted from *Brassicaceae* and precursors of isothiocyanates (ITCs), have been studied in the last decades mostly due to their

chemopreventive activity and, more recently, for their potential use as novel chemotherapeutics. The aim of the present study was to investigate the *in vitro* and *in vivo* activity of glucomoringin (GMG), an uncommon member of the GLs family, and to compare it with glucoraphanin (GRA), one of the most studied GL. We have evaluated the potency of both compounds in inducing cell death, cell cycle perturbations, apoptosis, NF- κ B inhibition and GST- π activity in human carcinoma cells with different GST- π contents as well as in human multiple myeloma and leukaemia cell lines. GMG-derived ITC (GMG-ITC) showed to be more effective compared to GRA-derived ITC (Sulforaphane), especially in inhibiting NF- κ B activity and inducing apoptosis through a caspase-dependent pathway; these effects were more pronounced in myeloma cells, in which we could also observe a long lasting growth inhibitory effect, probably due to NF- κ B inhibition, which is considered essential for myeloma cell survival. Both GLs were able to induce cell death in the μ M range in all tested cell lines but caused cell cycle perturbations only in myeloma cells; they were also able to modulate the GST/GSH pathway by causing a 3-fold increase in GST- π activity in MCF7 cells. *In vivo* study showed that pure GMG-ITC was only slightly active in a carcinoma mice model, whereas it had significant antitumoral activity in a myeloma model, causing little toxicity.

KEYWORDS: isothiocyanate; glucosinolate; myeloma; NF- κ B; sulforaphane

1 INTRODUCTION

Vegetables are important sources of compounds with cancer chemopreventive activity [1,2]. Among them are isothiocyanates (ITCs), species generated in *Brassicaceae* such as broccoli, Brussels sprouts and cauliflower, and they have attracted a lot of research interest as modulators of tumor growth since the original observation by Sidransky's group [3]. In vegetables, ITCs are stored in the form of inactive precursors called glucosinolates (GLs) and can be released after tissue damage by enzymatic hydrolysis involving myrosinase (MYR, E.C. 1.2.1.147), a thioglucoside glucohydrolase that is physically separated from GLs under normal conditions [4,5]. As the intestinal microflora of mammals, including humans, possess myrosinase-like activity, GLs can also be converted into ITCs in the mammalian digestive tract [6,7]. ITCs have been reported to inhibit tumor growth in different preclinical *in vivo* studies [8-10]. Moreover, epidemiological studies have shown an inverse relationship between dietary consumption of *Brassicaceae* and risk of developing lung, breast and colon cancer [11-13]. ITCs have many effects through which they may exert their protective action against cancer progression: they can induce phase-2 drug metabolizing enzymes like glutathione-S-transferase (GST) and quinone-reductase (QR) [14-17] through a Nrf-2 pathway, cause cell cycle arrest and apoptosis [18-20] and inhibit phase-I drug metabolizing enzymes and NF-kB related genes [20-22]. Sulforaphane (4-methylsulfinylbutyl isothiocyanate) is an ITC which has been extensively studied in recent years, as it was found to possess cancer chemopreventive and chemotherapeutic properties in a variety of preclinical models [9,13,22]. Glucomoringin (GMG) (4(alpha-L-rhamnosyloxy)-benzyl isothiocyanate) is an atypical GL due to the presence of a second saccharide residue in the aglycon side chain which might confer biological properties on the GL scaffold which are distinctly different from those of other members of the family (Fig.1). In the light of the putative role of sulforaphane and other ITCs [8] in cancer management, we wanted to characterize potential cancer chemotherapeutic properties of GMG-ITC. The cytotoxicity, cell cycle phase

perturbation, GST activity modulation, NF- κ B regulation, apoptosis induction and caspase activation induced by myrosinase-activated GMG (MA-GMG) were investigated *in vitro* in various carcinoma, leukaemia and myeloma cell lines and compared with those of sulforaphane generated from glucoraphanin (MA-GRA). Finally, since the *in vitro* studies revealed a much greater potency of MA-GMG on myeloma cells compared to both leukemia and carcinoma cells, chemically purified GMG-ITC was also tested in a preliminary *in vivo* study comparing its anti-neoplastic activity in mice bearing either human myeloma or carcinoma in order to confirm the increased efficacy on myelomas and to address its potential as a novel chemotherapeutic.

2 MATERIALS AND METHODS

2.1 Isolation and purification of compounds

GMG and GRA were isolated respectively from *Moringa oleifera* L. (fam. *Moringaceae*) and *Brassica oleracea* L. (fam. *Brassicaceae*; var. *acephala*; subvar. *laciniata*) seeds. Both GLs were purified in two sequential steps, by anion exchange and size exclusion chromatography, according to previously reported methods [23,24]. Individual GLs were characterised by ^1H and ^{13}C NMR spectrometry and the purity was assayed by HPLC analysis of the desulfo-derivative according to the ISO 9167-1 method (EEC Regulation No 1864/90 Enclosure VIII. Offic. Eur. Commun. L170: 27-34) resulting about 99% based on peak area value, but about 90-92% on weight basis due to their high hygroscopic properties. The enzyme MYR was

isolated from seeds of *Sinapis alba* L. according to a reported method [25] with some modifications. The stock solution used in the present study had a specific activity of ~60 units/mg of soluble protein and was kept at 4°C after dilution in H₂O at 34 U/ml. One MYR unit was defined as the amount of enzyme able to hydrolyse 1 µmole/min of sinigrin at pH 6.5 and 37°C. the MYR solution was stored at 4°C in sterile distilled water until use. GLs were dissolved in H₂O at a concentration of 1 mM, and kept at -20°C. Just before use, the solutions were diluted in medium at the desired concentration.. In every treatment made 5 µl of Myr for every 1.5 ml of GLs solutions were added in order to produce the active ITCs. GMG-ITC was produced via MYR catalyzed hydrolysis of GMG, performed in 0.1 M phosphate buffer pH = 6.5 at 37°C. The total conversion of pure GMG into GMG-ITC was confirmed by HPLC analysis of the desulfo-derivative (EEC Regulation No 1864/90 Enclosure VIII. Offic. Eur. Commun. L170: 27-34), which allowed us to monitor the reduction until complete disappearance of GMG in the reaction mixture. Acetonitrile was then added to the mixture until the final concentration was 20% and GMG-ITC was purified by reverse-phase chromatography, which was performed using a HR 16/10 column packed with LiChrospher RP-C18 (MERCK), connected to a GradiFrac System (Pharmacia). After washing with acetonitrile 20%, elution was carried out with a gradient up to 60% acetonitrile. Fractions were collected and analysed using a Hewlett-Packard Model 1100 HPLC system with an Inertsil ODS3 column (250 x 3 mm, 5 mm). Chromatography was performed with 1 mL/min flow rate at 30°C by eluting with a linear gradient of water (A) and acetonitrile (B) from 30% B to 80 % in 20 min. Elution of GMG-ITC was detected by a diode array, monitoring the absorbance at 229 nm. Fractions containing GMG-ITC (peak purity > 99%) were collected, the solvent were removed by concentration in a rotary evaporator, and the final solution was freeze-dried. The GMG-ITC was characterized and unambiguously identified by ¹H- and ¹³C-NMR and mass spectrometry techniques.

2.2 Drugs, cells culture condition and experimental tumor models

The human ovarian cancer cell line A2780, the human NSCLC (non-small cell lung cancer) H460 WT and its sub-line H460 S5 were grown in RPMI 1640 medium (Cambrex, Bio Science, Verviers, Belgium) containing 10% fetal bovine serum (FBS) (Sigma-Aldrich Co. Ltd, UK), 1% (v/v) 200 mM L-glutamine (Cambrex). H460 S5 cell line was derived from the parental line transfected by calcium-phosphate method with pCDNA3 (Invitrogen, Carlsbad, Ca, USA), containing an insert coding for the antisense sequence of the GST- π protein; this line was maintained in selection by adding 5 μ l/ml of G418 (100 mg/ml). The human mammarian cancer cell lines MCF7 π and NEO were grown in DMEM medium (Cambrex) containing 10% fetal bovine serum (FBS), 1% (v/v) 200 mM L-glutamine, 1% Sodium Pyruvate 100 mM (Cambrex) and 1% MEM non essential amino acid solution 100x (Cambrex); both cell lines were maintained in selection by adding 5 μ l/ml of G418 (100 mg/ml). MCF7 π cell line was derived from wild type cells transfected with a plasmid containing an insert coding for the GST- π protein while MCF7 NEO cell line was transfected with an empty plasmid. RAW-NF κ B, a murine immortalized macrophage cell-line, stably transfected with the luciferase gene put under a promoter responsive only to NF κ B, was grown in RPMI-1640 medium with 10% inactivated FBS (HyClone, Utah) and 1% (v/v) L-glutamine (200 mM). The human myeloid myeloma cell line RPMI-8226 was maintained in RPMI-1640 medium with 10% inactivated FBS and 1% (v/v) L-glutamine (200 mM). The human myeloid leukaemia cell line HL60 was maintained in RPMI-1640 medium with 10% inactivated FBS and 1% (v/v) L-Glutamine (200 mM). All cell lines were kept at 37 °C in a

humidified 5% CO₂ atmosphere in T-25-cm² tissue culture flasks (IWAKI, Bibby Sterilin, Staffordshire, UK). All cell lines used are stable immortalized cancer cell lines and experiments were performed with cells not exceeding 30 passages. For *in vivo* studies 4 to 6-week-old female CD1 *nu/nu* mice (Charles River, Calco, Lecco, Italy) and 5-week old male SCID mice were used. Mice were maintained under specific pathogen-free conditions, and provided food and water *ad libitum*. Procedures involving animals and their care are conducted in conformity with the institutional guidelines that are in compliance with national (D.Ln.116, G.U., suppl. 40, 18 Febbraio 1992, Circolare No. 8, G.U., 14 Luglio 1994) and international laws and police (EEC Council Directive 86/609, OJ L 358, 1, Dec. 12, 1987; Guide for the use of laboratory animals, United State National Research Council, 1996). Human ovarian A2780 cancer cells (8*10⁶ cell/mouse) and human myeloma RPMI8226 cancer cells (30*10⁶ cell/mouse) were implanted s.c. into the flank of recipient mice. When tumor was palpable (mean tumor weight value for the groups was 100-150 mg for the RPMI8226 bearing mice and 50-100 mg for the A2780 bearing mice respectively), animals were divided randomly into test groups consisting of 6-8 mice each, according to *Geran et al.* Tumor growth was measured every two days using a calliper. GMG-ITC was dissolved in H₂O:Tween 5% and drug solutions were prepared every day before treatments; mice were treated i.p. daily, 5 days a week for 2-3 weeks with 20 mg/kg of GMG-ITC.

2.3 Flow cytometric DNA cell cycle analysis

Exponentially growing cells were treated for 24 hours with different concentration of myrosinase-activated-GLs. At the end of treatment and at different time intervals after drug-

washout the cells were counted by a Coulter Counter Channelyzer 256 (Beckman Coulter) and fixed in 70% cold ethanol and kept at 4°C. The cells were washed with cold PBS and stained with a 1 ml solution containing 5 µg/ml propidium iodide in PBS and 12.5 µl/ml RNase 1% in water overnight in the dark. Flow cytometric cell cycle analysis were performed on at least 20.000 cells by using FACS Calibur instrument (Becton Dickinson, Sunnyvale, CA, USA). Fluorescence pulses were detected using a laser beam at 488 nm and a band pass filter 620±35 nm, for red fluorescence, in combination with a dichroic mirror at 570 nm. [26]. Percentages of distribution of cells in the phases of the cell cycles were analyzed according to the method by Bertuzzi et al.[27]

2.4 Cell death

Apoptosis was evaluated by two different methods: TUNEL Assay and Caspase-3 activation. TUNEL assay was performed following this protocol: at the end of treatment, and at different time intervals after drug washout, the cells were fixed in 70% ethanol and kept at 4°C before staining. The fixed cells were washed in cold PBS and permeabilized with 0.25% Triton X-100 (Sigma) in PBS for 5 minutes in ice. After removing Triton X-100, cells were incubated in 50 µl of solution containing terminal-dUTP-transferase (TdT) and FITC-conjugated dUTP deoxynucleotides 1:1 in storage buffer (Boehringer Mannheim, Germany) for 90 min at 37 °C in the dark. Caspase-3 activation was assessed by fixing cells in 1% paraformaldehyde for 1 hour in ice and, subsequently, in 70% ethanol. Cells were washed in PBS and permeabilized for 10 minutes with 0.004% saponin in PBS supplemented with 0.5% BSA and 5 mM EDTA. After centrifugation cells were resuspended with 20 µl of anti-active caspase-3 direct PE-antibody (BD Biosciences, Pharmingen, Canada) for 1 hour in the dark. Flow cytometric

analysis were performed on at least 20.000 cells by using FACS Calibur instrument. Fluorescence pulses were detected using a laser beam at 488 nM and a band pass filter 530±25 nm for FITC fluorescence and 585±45 nm for PE fluorescence.

2.5 Luciferase Assay

For this assay we used a commercial kit (E1500, Promega, Madison, WI, USA). Briefly, RAW-NFkB cells were plated in 6 wells Petri at 150000 cells/ml (2 ml/well) and 24 hours later were treated with different concentrations of myrosinase-activated-GLs. After 24 hours cells were washed with cold PBS and we added Passive Lysis Buffer (1X) for 10 minutes to lyse the membranes. The pellet was then collected, centrifuged, and supernatant kept at – 20°C. Proteins were quantified by a standard kit (BioRad, USA) and 20 µl were put in a round-bottom tube (Becton Dickinson, MA, USA). For every 25 µl of protein solution 50 µl of Luciferase Substrate were added and the samples were read with a Lumat LB 9057 (EG&G BERTHOLD) luminometer for 10 seconds.

2.6 NF-kB activity assay

This assay was performed using a commercial kit (EZ-DETECT NfκB p50 Transcription Factor Kit, PIERCE, Rockford, IL, USA) which, by using plates coated with specific NF-kB DNA consensus sequences to which only the active NF-kB complex can ligate, can minimize

nonspecific binding. Exponentially growing RPMI-8226 cells were treated for 24 h with different concentrations of myrosinase-activated-GLs. After the end of the treatment and 24 hours after drug washout cells were lysed using RIPA extraction buffer. The pellet was then collected, centrifuged, and supernatant kept at -20°C . Proteins were quantified by a standard kit (BioRad). Proteins were subsequently utilized to detect NF- κ B activity following manufacturer instructions.

2.7 GST- π activity assay

Exponentially growing MCF-7 cells were treated for 24 h with different concentration of myrosinase-activated-GLs. After treatment cells were scraped and resuspended in H_2O , sonicated and centrifuged and thereafter the supernatant was used to determine both protein concentration and GST activity. Proteins were quantified by a standard kit (BioRad, USA) and GST- π activity by monitoring the conjugation of glutathione with 1-chloro-2,4-dinitrobenzene (CDNB) following Habig protocol (Habig *et al.*, 1974). Briefly, 100 μl of proteins were put in solution with 100 μl GSH 10mM, 100 μl Phospate Buffer, 680 μl H_2O and 20 μl CDNB 50 mM; the increase in the absorbance at 340 nm generated by the conjugation reaction was then followed for 1 minute using a spectrophotometer (UVIKRON-860, Kontron Instrument) and the results expressed as percentage of control activity.

3 RESULTS

3.1 Growth inhibition and cell cycle effects

In preliminary studies exposure-efficacy conditions for MA-GMG and MA-GRA in various human carcinoma cell lines were optimised using the MTT assays (data not shown). The effects incremented by increasing the exposure time up for 24 h but only a modest increase was observed for 48 and 72 h exposures; 24 h treatment was, thus, considered as the optimal exposure time for the subsequent experiments. Due to the suggested role of the GST/GSH pathway in modulating ITCs cytotoxicity [12,14,16], ability of both MA-GMG and MA-GRA to induce cell death was subsequently studied using cell count assays in two pairs of isogenic carcinoma cell systems with a 2-fold (H460 WT / S5) or 25-fold (MCF7 π / NEO) difference in GST- π content. MA-GMG showed an IC₅₀ range of 18–29 μ M while MA-GRA was slightly less potent with a range of 19–30 μ M (Table 1). A small increase in potency of both compounds was present in the H460 S5 cell line compared to its WT counterpart but, on the other hand, no differences could be observed in the MCF7 model thus suggesting that this is probably not a major determinant in GCs cytotoxicity. To evaluate whether growth inhibition was associated with an alteration in cell cycle phase distribution, we also performed flow cytometric DNA cell cycle analysis on all the four cell lines. The ITCs did not cause any significant alteration in cell cycle phases distribution (Fig.1) (data not shown).

3.2 Effects on GST- π activity

To better understand the potential role of the GST/GSH pathway in ITCs mechanism of action, we evaluated the effects of MA-GMG and MA-GRA on GST- π activity using the isogenic cell lines MCF7 NEO and MCF7 π : This model was preferred to the H460 one due to the increased differences in basal GST- π activity between the two cell lines thus permitting a more sensitive and accurate measurement of the effects. Enzymatic activity was measured 24 hour after ITCs treatment and results are shown in Fig.2. Both compounds induced GST- π activity in MCF7 NEO cells by 2.5 to 3.5-fold, whilst there was no significant induction in the MCF7 π line. Various studies [28,29] have related the growth-modulating activity of ITCs to their ability to deplete cellular GSH, thus rendering cells vulnerable to oxidative stress and apoptotic signalling. To explore whether the cytotoxic effect of MA-GMG and MA-GRA might have been caused by GSH depletion, we exposed MCF7 π and NEO cells to MA-GMG and MA-GRA after pre-treatment with the GSH-depleting agent BSO (buthionine sulfoximine). Pre-treatment with BSO failed to modify significantly the cytotoxic potential of either compound (data not shown).

3.3 Effects on NF-kB dependent gene expression

The transcription factor NF-kB is responsible for many cellular signalling pathways and changes in NF-kB-dependent gene regulation is often associated with tumorigenesis. In the light of the NFkB-inhibiting properties of sulforaphane [21,22] we studied the effects of MA-GMG and MA-GRA on NF-kB in RAW NF-kB cells. MA-GMG inhibited NF-kB activity, expressed as luciferase level, in a dose-dependent manner (Fig.3). Maximal inhibition (by

70%) was observed at 30 μ M. In contrast MA-GRA did not depress NF κ B activity by more than 30%. Since the survival of many human myeloma cell lines seems to be exquisitely sensitive towards alterations in NF- κ B related pathways [30-32], we decided to further investigate the ability of MA-GMG or MA-GRA to inhibit NF- κ B using the human multiple myeloma cell line RPMI-8226. Fig.4 shows NF- κ B activity at the end of treatment with MA-GMG or MA-GRA and 24 hours after drug washout. MA-GMG inhibited NF- κ B activity in these cells in a dose dependent manner at lower concentrations than those used in the experiments employing RAW NF- κ B cells described above. The inhibitory effect of MA-GMG was maintained up to 24 h after drug washout, whilst that of MA-GRA was reversed after treatment. The importance of NF- κ B inhibition in RPMI-8226 cell survival was further confirmed with the use of parthenolide and cymaropicrin, two previously reported NF- κ B inhibitors, which showed comparable results with those obtained with ITCs and a very strong correlation between NF- κ B inhibition and growth inhibition (supplementary materials)

3.4 Cell cycle perturbation and apoptosis induction on myelomas

Considering the NF- κ B inhibition observed in the RPMI-8226 cell line even at low drug concentrations, we decided to further investigate the growth inhibitory and cell cycle perturbation effects of both MA-GMG and MA-GRA using this model. Fig.5 shows that the growth inhibitory effect of both ITCs was 3-4 fold greater than those observed in carcinoma derived cell lines reaching an IC₅₀ of 6-7 μ M and, most noticeably, it was correlated with a strong cell cycle perturbation mainly due to a G₂M phase block (Table 2). To address if the observed increase in sensitivity was due to the different nature of the myeloma cells compared

to carcinoma-derived tumor cells, we performed the same experiments also on another myeloid-derived tumor which is typically quite sensitive to drug treatments, HL60; our results demonstrates that this was not the case since the IC₅₀s of 15-16 μ M obtained with both drug treatments were comparable to those obtained in solid tumor cells (Fig.6). It has been reported that GL-derived ITCs act as apoptotic inducers [18-20], thus we investigated this mechanism of cell death, once again, both on carcinoma-derived and myeloid-derived cell lines. After MA-GMG or MA-GRA exposure, H460 WT and H460 S5 cell lines showed no apoptosis induction (data not shown) and the same results were also obtained with HL60 cells (Fig.7, right upper panel) while, on the other hand, both compounds induced apoptosis in RPMI-8226 cells (Fig.7, left upper panel) and the percentage of apoptotic cells detected was higher after MA-GMG treatment. Apoptotic cells were already detectable after 6 hours exposure (data not shown). With the aim of understanding whether the apoptotic process was caspase-3 dependent, we also marked cells with an anti-caspase antibody (Fig.7, lower panel). The results showed a nearly perfect correlation between the percentages of apoptotic and caspase-3 activated cells for both the RPMI-8226 (lower left panel) and HL60 (lower right panel) suggesting that the caspase pathway is the main, if not the only, pathway involved in this apoptotic process.

3.5 GMG-ITC activity in experimental tumor mouse model

In order to evaluate its potential use as an antineoplastic agent against carcinomas or myelomas, GMG-ITC was administered to two different murine cancer models. In the first model, Swiss Ncr *nu/nu* mice bearing A2780 ovarian cancer were treated daily, 5 days a

week, for 2 weeks with i.p. injections of either 20 mg/kg GMG-ITC or an equivalent volume of vehicle solution. Treated mice showed a reduced tumor growth (Fig.8, upper panel), with the difference between the two groups becoming statistically significant starting from day 13, 3 days after the end of the treatment period. No toxicity was observed during the whole experimental period but, despite the reduced growth observed in treated mice, T/C values did not indicate a significant antitumoral activity with the best T/C value of 53.8 %. In the second model, SCID mice bearing RPMI-8226 myeloma received either GMG-ITC or vehicle solution following the same schedule used in the former experiment. Mice receiving GMG-ITC showed a significantly slower tumor growth rate compared to controls starting from day 8 (Fig.8, lower panel). Toxicity was not observed (Max BWL = 7,8 %) and T/C values demonstrated a statistically significant difference between the two groups with a best T/C of 33.9%. For this reason, treatment was continued into a 3rd week. At the end of the 3rd week GMG-ITC started to show toxicity with 2 out of 8 mice dying.

4 DISCUSSION

GL-derived ITCs have been intensively studied in the last years due to their chemopreventive effects and, more recently, various studies demonstrated their potential use as novel chemotherapeutics [9,13,22]. GMG is an uncommon member of the GLs family and presents a unique characteristic consisting in a second saccaridic residue in its side chain. This GLs is a typical secondary metabolite present in vegetables belonging to the genus *Moringaceae* that consists of 14 species, among which *M. oleifera* is the most widely distributed. *M. oleifera* is a multipurpose tree which grows in many tropical or equatorial regions. The medical value of

the seeds and other part of the plant have long been recognized in folk medicine [33]. The glycosylated ITC, resulting from myrosinase-hydrolysis of GMG, has been shown to exhibit a broad biological activity [33] and it was also shown to exert an effective antitumor activity [34]. GMG-ITC is a solid, odorless, and stable compound at room temperature that can be purified easily in high amounts differing from others natural bioactive ITCs which are liquid, volatile, with pungent odors and usually present at lower concentrations. What we presented in this study represent the first data on this molecule and our findings demonstrate its potential use as a novel chemotherapeutic compound, especially considering its overall increased potency compared to the most studied ITC, Sulforaphane. Our first experiments were aimed at determining the best time-exposure protocols and concentration range of activity of the two molecules in various human carcinoma cell lines, resulting in an optimal 24 hours schedule of treatment at μM concentrations. The cell cycle analysis showed that both ITCs are unable to induce detectable cell cycle perturbations while still being able to significantly inhibit cell growth suggesting that in those cell lines, probably, ITCs do not activate a specific cell cycle checkpoint but slow down the progress of cells through all phases of cell cycle. Various studies have demonstrated that ITCs are able to induce phase-2 drug metabolizing enzymes and, among them, Glutathione-S-Transferase (GST) [14-17] has always been considered of great importance for these compounds to exert their effects. We investigated the ability of MA-GMG and MA-GRA to modulate GST- π activity in two isogenic cell lines (MCF7 π and NEO) with a 25 fold relative difference in GST- π basal activity. Our results suggest that, despite the partial influence shown by ITCs on the GST/GSH system, their cytotoxic effects are not as closely related to this. Both compounds, infact, did not show a significant increase in their potency even when coupled with the GSH depleting agent BSO (data not shown) despite being able to induce a 2,5 to 3,5 fold increase in its activity in **MCF7 NEO** cells. The NF- κ B pathway is often associated with tumorigenesis

when deregulated and, since it has been shown that ITCs can also modify the expression of various genes associated with inflammatory response [14-22], we decided to compare MA-GMG and MA-GRA effects on the expression of NF- κ B and NF- κ B dependant genes. Our experiments showed that both drugs were able to significantly downregulate NF- κ B activity with MA-GMG showing a good dose-responsiveness with a peak of 70 % inhibition at 30 μ M and MA-GRA being less potent with a 30 % inhibition peak. Due to the great importance of NF- κ B related pathway in myeloma cells survival [30-32], we subsequently tested both compounds also on the RPMI-8226 human multiple myeloma cell line; both drugs showed an increased inhibitory effect in these cells with 40 % inhibition already at 10 μ M. Most noticeably, MA-GMG effect lasted up to 24 hours after drug washout. In light of these results, we decided to perform also cell count assays and cell cycle analysis to better evaluate the potency of GL-derived ITCs on this type of malignant cells compared to carcinomas. Our experiments not only showed that both MA-GMG and MA-GRA were able to induce a stronger growth inhibitory effect and at lower doses (5-15 μ M) but also that both drugs were able to induce long lasting cell cycle perturbations mostly consisting in G₂M accumulation. To highlight if this greater potency was due to the different heritage of myeloid-derived tumors compared to carcinomas, we performed the same experiments on the HL60 leukemia cell line. The results obtained demonstrated that this was not the case since HL60 cells did not show an increased sensitivity to MA-GMG or MA-GRA treatments compared to carcinoma cells, with a comparable IC₅₀ of 15 μ M. We also report here that both ITCs are able to induce caspase-3 dependant apoptosis in multiple myeloma cells but not in other myeloid nor carcinoma cells (data not shown). Even in this case MA-GMG showed a stronger and longer lasting effect when compared to MA-GRA. To confirm our *in vitro* data we finally performed a preliminary *in vivo* test comparing the activity of the purified GMG-ITC in two different mice models bearing either a carcinoma or a myeloma. As expected, GMG-ITC showed little

activity in the carcinoma model reaching a best T/C value of 53,8 % while, on the contrary, it was able to statistically affect the tumor growth rate in the myeloma model reaching a best T/C of 33,9 % and maintaining a statistically significant activity for more than 14 days (from day 4th to day 18th). The mechanism of action of GL-derived ITCs still remains largely unknown but the results presented in this paper, showing an increased sensitivity of myeloma cells compared to carcinoma cells to ITC treatment both *in vitro* and *in vivo*, suggest that the inhibitory effects on NF- κ B activity may play a key role in their activity considering that myelomas are known to strongly depend on NF- κ B expression for their growth. Recently, the proteasome inhibitor Velcade was found effective on myelomas [35-37] and it was suggested that the reason for its specificity is linked to the reduced catabolism of I κ B which, in turns, inhibit NF- κ B activation. Multiple myeloma still remains one of the malignancies with the highest mortality and for this reason, despite new therapies with Velcade have improved the chances of survival for myeloma's patients, the need for new and improved drugs is still high. We envision the possibility that other drugs active on NF- κ B inhibition, could have some potential for the treatment of myelomas and, in this respect, GL-derived ITCs could be possible candidates considering their relatively low toxicity. GMG-ITC seems to be a good candidate for further investigating ITCs potential in myeloma treatment since our results demonstrate that it is more potent than the commonly studied Sulforaphane and, in addition, it is easily extracted from the seeds of *M.oleifera* where it represents roughly 8-10 % of the whole weight, thus making GMG one of the most available and probably also the most economic GL to obtain and purify.

Acknowledgements

The generous contribution of the Italian Association for Cancer Research (AIRC) and Fondazione Mattioli to the Department of Oncology of Mario Negri Institute is greatly appreciated. This study was conducted with the financial support of Indena S.p.A.

Conflict of interest:

Carla Manzotti and Carlo Morazzoni are employees of Indena S.p.A. who supported the study

References

- [1] D'Incalci M, Steward WP, Gescher AJ. Use of cancer chemopreventive phytochemicals as antineoplastic agents. *Lancet Oncol.* 2005;6(11):899-904
- [2] D'Incalci M., Brunelli D., Marangon E., Simone M., Tavecchio M., Gescher A. and Mantovani R. Modulation of gene transcription by natural products - a viable anticancer strategy. *Curr Pharm Design* 2007;13(27):2744-2750
- [3] Sidransky H, Ito N, Verney E. Influence of alpha-naphthyl-isothiocyanate on liver tumorigenesis in rats ingesting ethionine and N-2-fluorenylacetamide. *J Natl Cancer Inst.* 1966;37(5):677-686.
- [4] Fenwick GR., Heaney RK., and Mullin WJ. Glucosinolates and their breakdown products in food and food plants. *Crit. Rev. Food Sci. Nutr.* 1983;18(2):123–201

- [5] Fahey JW., Zalcmann AT., and Talalay P. The chemical diversity and distribution of glucosinolates and isothiocyanates among plants. *Phytochemistry* 2001;56(1):5–51.
- [6] Shapiro TA, Fahey JW, Wade KL, Stephenson KK, Talalay P. Human metabolism and excretion of cancer chemoprotective glucosinolates and isothiocyanates of cruciferous vegetables. *Cancer Epidemiol Biomarkers Prev.* 1998;7(12):1091-1100
- [7] Getahun SM, Chung FL. Conversion of glucosinolates to isothiocyanates in humans after ingestion of cooked watercress. *Cancer Epidemiol Biomarkers Prev.* 1999;8(5):447-451
- [8] Zhang Y, Talalay P. Anticarcinogenic activities of organic isothiocyanates: chemistry and mechanisms. *Cancer Res.* 1994;54(7 Suppl):1976-1981.
- [9] Hecht SS. Inhibition of carcinogenesis by isothiocyanates. *Drug Metab. Rev.* 2000;32(3-4):395-411.
- [10] Conaway CC., Yang YM. and Chung FL. Isothiocyanates as cancer chemopreventive agents: their biological activities and metabolism in rodents and humans. *Curr. Drug Metab.* 2002;3(3):233–255.
- [11] Fowke JH, Chung FL, Jin F, Qi D, Cai Q, Conaway C, Cheng JR, Shu XO, Gao YT, Zheng W. Urinary isothiocyanate levels, brassica, and human breast cancer. *Cancer Res.* 2003;63(14):3980-6.
- [12] Zhao B, Seow A, Lee EJ, Poh WT, Teh M, Eng P, Wang YT, Tan WC, Yu MC, Lee HP. Dietary isothiocyanates, glutathione S-transferase -M1, -T1 polymorphisms and lung cancer risk among Chinese women in Singapore. *Cancer Epidemiol Biomarkers Prev.* 2001;10(10):1063-7
- [13] Conaway CC, Wang CX, Pittman B, Yang YM, Schwartz JE, Tian D, McIntee EJ, Hecht SS, Chung FL. Phenethyl isothiocyanate and sulforaphane and their N-acetylcysteine conjugates inhibit malignant progression of lung adenomas induced by tobacco carcinogens in A/J mice. *Cancer Res.* 2005;65(18):8548-8557.

- [14] Steinkellner H., Rabot S., Freywald C., Nobis E., Scharf G., Chabicovsky M., Knasmüller S. and Kassarjian F. Effects of cruciferous vegetables and their constituents on drug metabolizing enzymes involved in the bioactivation of DNA-reactive dietary carcinogens. *Mutat. Res.* 2001;480–481:285–297.
- [15] Talalay P. and Fahey JW. Phytochemicals from cruciferous plants protect against cancer by modulating carcinogen metabolism. *J. Nutr.* 2001;131(11 Suppl.):3027–3033.
- [16] Brooks JD., Paton VG. and Vidanes G. Potent induction of phase 2 enzymes in human prostate cells by sulforaphane. *Cancer Epidemiol. Biomarkers. Prev.* 2001;10(9): 949–954.
- [17] McWalter GK, Higgins LG, McLellan LI, Henderson CJ, Song L, Thornalley PJ, Itoh K, Yamamoto M, Hayes JD. Transcription factor Nrf2 is essential for induction of NAD(P)H:quinone oxidoreductase 1, glutathione S-transferases, and glutamate cysteine ligase by broccoli seeds and isothiocyanates. *J. Nutr.* 2004;134(12 Suppl):3499-3506.
- [18] Fimognari C, Nusse M, Cesari R, Iori R, Cantelli-Forti G, Hrelia P. Growth inhibition, cell-cycle arrest and apoptosis in human T-cell leukemia by the isothiocyanate sulforaphane. *Carcinogenesis.* 2002;23(4):581-6.
- [19] Bonnesen C., Eggleston IM. and Hayes JD. Dietary indoles and isothiocyanates that are generated from cruciferous vegetables can both stimulate apoptosis and confer protection against DNA damage in human colon cell lines. *Cancer Res.* 2001;61(16):6120–6130.
- [20] Srivastava SK, Singh SV. Cell cycle arrest, apoptosis induction and inhibition of nuclear factor kappa B activation in anti-proliferative activity of benzyl isothiocyanate against human pancreatic cancer cells *Carcinogenesis* 2004;25(9):1701-9
- [21] Xu C, Shen G, Chen C, Gelinas C, Kong AN. Suppression of NF-kappaB and NF-kappaB-regulated gene expression by sulforaphane and PEITC through IkappaBalpha, IKK pathway in human prostate cancer PC-3 cells. *Oncogene.* 2005;24(28):4486-4495.

- [22] Heiss E, Herhaus C, Klimo K, Bartsch H, Gerhauser C. Nuclear factor kappa B is a molecular target for sulforaphane-mediated anti-inflammatory mechanisms. *J. Biol. Chem.* 2001;276(34):32008-32015
- [23] Barillari J, Gueyrard D, Rollin P, Iori R. Barbarea verna as a source of 2-phenylethyl glucosinolate, precursor of cancer chemopreventive phenylethyl isothiocyanate. *Fitoterapia* 2001;72(7):760-4.
- [24] Barillari J, Canistro D, Paolini M, Ferroni F, Pedulli GF, Iori R, Valgimigli L. Direct antioxidant activity of purified glucoerucin, the dietary secondary metabolite contained in rocket (*Eruca sativa* Mill.) seeds and sprouts. *J. Agric. Food. Chem.* 2005;53(7):2475-2482.
- [25] Pessina A, Thomas RM, Palmieri S, Luisi PL. An improved method for the purification of myrosinase and its physicochemical characterization. *Arch. Biochem. Biophys.* 1990;280(2):383-9.
- [26] Simone M, Erba E, Damia G, Vikhanskaya F, Di Francesco AM, Riccardi R, Bailly C, Cuevas C, Fernandez Sousa-Faro JM, D'Incalci M. Variolin B and its derivate deoxy-variolin B: new marine natural compounds with cyclin-dependent kinase inhibitor activity. *Eur. J. Cancer* 2005;41(15):2366-2377.
- [27] Bertuzzi A, Gandolfi A, Germani A, Spanò M, Starace G, Vitelli R. Analysis of DNA synthesis rate of cultured cells from flow cytometric data. *Cytometry*. 1984 Nov;5(6):619-628
- [28] Zhang Y. Role of glutathione in the accumulation of anticarcinogenic isothiocyanates and their glutathione conjugates by murine hepatoma cells. *Carcinogenesis*. 2000;21(6):1175-1182.
- [29] Zhang Y. and Talalay P. Mechanism of differential potencies of isothiocyanates as inducers of anticarcinogenic Phase 2 enzymes. *Cancer Res.* 1998;58(20):4632–9.
- [30] Ito K, Nakazato T, Xian MJ, Yamada T, Hozumi N, Murakami A, Ohigashi H, Ikeda Y, Kizaki M. 1'-acetoxychavicol acetate is a novel nuclear factor kappaB inhibitor with

significant activity against multiple myeloma in vitro and in vivo. *Cancer Res.*

2005;65(10):4417-4424.

[31] Yinjun L, Jie J, Yungui W. Triptolide inhibits transcription factor NF-kappaB and induces apoptosis of multiple myeloma cells. *Leuk. Res.* 2005;29(1):99-105.

[32] Feinman R, Koury J, Thames M, Barlogie B, Epstein J, Siegel DS. Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. *Blood.* 1999;93(9):3044-3052.

[33] Anwar F., Latif S., Ashraf M., Gilani A.H. *Moringa oleifera*: A food plant with multiple Medicinal Uses. *Phytother. Res.* 2007;21(1):17-25

[34] Guevara AP., Vargas C., Sakurai H., Fujiwara Y., Hashimoto K., Maoka T., Kozuka M., Ito Y., Tokuda H., Nishino H. An antitumor promoter from *Moringa oleifera* Mutat. *Res.* 1999;440(2):181-8.

[35] Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC The Proteasome Inhibitor PS-341 Inhibits Growth, Induces Apoptosis, and Overcomes Drug Resistance in Human Multiple Myeloma Cells *Cancer Res.* 2001;61(7):3071-6

[36] LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, Neuberg D, Goloubeva O, Pien CS, Adams J, Gupta D, Richardson PG, Munshi NC, Anderson KC. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. *Cancer Res.* 2002;62(17):4996-5000.

[37] Altun M, Galaray PJ, Shringarpure R, Hideshima T, LeBlanc R, Anderson KC, Ploegh HL, Kessler BM. Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells. *Cancer Res.* 2005;65(17):7896-7901

Figure Captions

Fig.1: Chemical structures of Glucosinolates and GMG and GRA side chains.

Fig.2: GST- π activity in MCF7 π (white columns) and MCF7 NEO (black columns) cells evaluated after 24 hours MA-GMG or MA-GRA treatment. Results are shown as percentage of relative controls. Error bars represent the standard deviation. Statistical analysis: *:p<0,01 **:p<0,005 ***:p<0,001 compared with untreated controls.

Fig.3: NF-kB-dependent luciferase expression in RAW NF-kB after 24 hours treatment with MA-GMG (black columns) or MA-GRA (white columns). Data shown are mean values of 3 experiments each consisting of 3 replicates. Error bars represent the standard deviation. Statistical analysis: *:p<0,01 **:p<0,005 ***:p<0,001 compared with untreated controls. #:p<0,01 ##:p<0,005 ###:p<0,01 compared with MA-GMG treatments.

Fig.4: NF-kB activity in RPMI-8226 cell line evaluated after 24 hours treatment with MA-GMG or MA-GRA and 24 hours after drug washout. Data shown are mean values of 2 experiments each consisting of 3 replicates. Error bars represent the standard deviation. Statistical analysis: *:p<0,01 **:p<0,005 ***:p<0,001 compared with untreated controls. #:p<0,01 ##:p<0,005 ###:p<0,01 compared with MA-GMG treatments.

Fig.5: Growth inhibitory effects (right) and cell cycle phase perturbations (left) induced on RPMI-8226 cell treated for 24 hours with 0 (—*), 5 (—●—), 7,5 (—■—), 10 (—▲—) or 15 μ M (—◉—) of MA-GMG or MA-GRA. Error bars represent the standard deviation. IC₅₀ values were calculated 48 hours after drug washout. Statistical analysis: *:p<0,01 **:p<0,005 ***:p<0,001 compared with untreated controls.

Fig.6: Growth inhibition induced on HL60 cell by 24 hours treatment with 10 (—■—), 20 (—▲—) and 30 μ M (—●—) MA-GMG or MA-GRA. IC₅₀ values were calculated 48 hours after drug

washout. Error bars represent the standard deviation. Statistical analysis: *:p<0,01 **:p<0,005 ***:p<0,001 compared with untreated controls.

Fig.7: Detection of apoptosis (upper panel): RPMI-8226 (left) and HL60 (right) cells were treated for 24 hours with 10 μ M of MA-GMG or MA-GRA. The biparametric TdT-d-UTP / Forward scatter flow cytometric analysis were performed after 24 hours treatments and 24, 48 and 72 hours after drug-washout. The percentage of apoptotic cells are also reported.

Experiments were repeated three times with comparable results.

Detection of active caspase-3 (lower panel): RPMI-8226 (left) and HL60 (right) cells were treated for 24 hours with 10 μ M of MA-GMG or MA-GRA. The biparametric caspase-3 /Forward scatter flow cytometric analysis were performed after 24 hours treatment and 24, 48 and 72 hours after drug-washout. The percentage of caspase-3 positive cells are also reported.

Experiments were repeated three times with comparable results.

Fig.8: Antitumoral activity of GMG-ITC on Swiss Ncr *nu/nu* mice bearing A2780 ovarian cancer (upper panel) or SCID mice bearing RPMI-8226 myeloma cancer (lower panel). Mice were treated with 20 mg/kg GMG-ITC i.p. once a day for 2 (*nu/nu* mice) or 3 (NUDE mice) weeks, 5 days a week. Result are shown as tumor weight of control (continuous line) and treated (crossed line) mice. Error bars represent the standard error. *: p<0,05 **: p<0,01 compared to control.

RESPONSE TO REVIEWERS:

Response to reviewer #1:

The reviewer suggested a few changes to the original paper, which were addressed as follow:

- 1- A picture showing the general chemical structure of glucosinolates and the side chains of both ITCs GMG and GRA was added to help with the understanding of the potential

differences in chemical properties suggested in the paper (this figure has been named Fig.1 in the revised paper)

- 2- Further details on the cells used and on their passage numbers has been indicated in the Material and Methods section
- 3- The previously named Fig.1 (now substituted with the figure showing the chemical structures of the compounds) showing the cell cycle analysis results on H460 and MCF-7 cell lines has been removed as suggested
- 4- Digits above bars in Fig.2 have been removed as suggested
- 5- All data were analyzed according to the method by Bertuzzi et al (Cytometry.1984 Nov;5(6):619-28. Analysis of DNA synthesis rate of cultured cells from flow cytometric data. Bertuzzi A,Gandolfi A,Germani A,Spanò M,Starace G,Vitelli R.) and percentages of cells in the various phases have been added in a separate table.
- 6- Caspase-3 activation and Apoptosis induction experiments as those depicted in Fig.7 were performed three times and gave reproducible results. Data presented are representative results of a typical experiment.
- 7- Table 1 was corrected as suggested by the reviewer to include data for MCF-7 Neo cell line

Response to reviewer #2:

In response to the suggestion to provide further evidence of the linkage between NF- κ B inhibition and ITCs cytotoxicity in multiple myeloma cell lines, we performed additional experiments using two additional natural compounds which have been previously reported to be NF- κ B inhibitors: cynaropicrin (*Br J Pharmacol.* 2008 Jun;154(4):852-63. Src kinase-targeted anti-inflammatory activity of davallialactone from *Inonotus xeranticus* in lipopolysaccharide-activated RAW264.7 cells. Lee YG, Lee WM, Kim JY, Lee JY, Lee IK, Yun BS, Rhee MH, Cho JY) and parthenolide (*Clin Cancer Res.* 2008 Mar 15;14(6):1814-22. Antimyeloma effects of a sesquiterpene lactone parthenolide. Suvannasankha A, Crean CD, Shanmugam R, Farag SS, Abonour R, Boswell HS, Nakshatri H).

Both compounds showed similar results to those observed with ITCs treatment, with a very strong correlation between percentage of NF- κ B inhibition and growth inhibition (see supplementary materials), thus confirming that NF- κ B pathway play a crucial role in multiple myeloma cell survival.

The analysis of GST- π was not extended to the multiple myeloma cell lines since we observed no differences in ITCs activity in both isogenic models we tested; these findings were further confirmed with the BSO experiments which, again, showed no differences in ITCs activity after GSH depletion.

Considering that this pathway showed no hint of being relevant to ITCs mechanism of action in all those experiments and also that we would have to purposely create a novel isogenic model with the RPMI-8226 cell line we considered superfluous further investigating this pathway.

The other specific points pointed out were addressed as follow:

- 1- A picture showing the general chemical structure of glucosinolates and the side chains of both ITCs GMG and GRA was added to help with the understanding of the potential differences in chemical properties suggested in the paper (this figure has been named Fig.1 in the revised paper).
- 2- All cell growth inhibition and MTT experiments were performed under the same conditions with the only difference being the initial concentration of seeded cells, which was modified according to the different cell lines in order to maintain an exponential growth for the complete duration of the experiment. The time-points for IC50 calculations were the same for both carcinomas and myelomas cells (48 hours after drug removal); since the legend for Table 1 was misleading, it was modified to better specify how IC50s values were calculated. Doubling times were comparable among the various cell lines (roughly between 19 and 24 hours depending on the cell line) and are not responsible for the differences observed.
- 3- Table 1 data have been corrected to show the right values for MCF7 NEO cell line.
- 4- Figure 1 was removed as suggested by another referee since it was considered superfluous. All flow cytometry experiments were repeated three times resulting in comparable results and data presented in the paper are representative results taken from a single experiment; figure captions have been modified to better specify the reproducibility of the presented data. All data were analyzed according to the method by Bertuzzi et al (Cytometry.1984 Nov;5(6):619-28. Analysis of DNA synthesis rate of cultured cells from flow cytometric data. Bertuzzi A,Gandolfi A,Germani A,Spanò M,Starace G,Vitelli R.) and percentages of cells in the various phases have been added in a separate table.
- 5- A more detailed description of the kit used in the experiments has been inserted in the Material and Methods section to better explain what we measured; this commercial kit detects only the active NF-kB complex by using plates coated with specific DNA sequences to which only the active complex can bind, thus minimizing nonspecific binding. Since the majority of the NF-kB complexes are made by the p50/p65 heterodimer, there should be no significant loss of specificity by using this kit.
- 6- GST- π induction was induced in MCF7 NEO cell line as shown in figure 2 and in result section; discussion was modified to correct the typing error.
- 7- NUDE mice were used for the A2780 experiment while SCID mice were used for the RPMI-8226 experiment as written in material and method section; the legend to figure 8 was changed to correct the typing error.

The isothiocyanate produced from Glucomoringin inhibits NF- κ B and reduces myeloma growth in nude mice *in vivo*

Dario Brunelli ^{a,*}, Michele Tavecchio ^a, Cristiano Falcioni ^a, Roberta Frapolli ^a, Eugenio Erba ^a, Renato Iori ^b, Patrick Rollin ^c, Jessica Barillari ^b, Carla Manzotti ^d, Paolo Morazzoni ^d, and Maurizio D'Incalci ^a

^(a)Laboratory of Cancer Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa 19, 20156 Milano, Italy

^(b)Agricultural Research Council, Research Center for Industrial Crops (CRA-CIN), Via di Corticella 133, 40129 Bologna, Italy

^(c) Institut de Chimie Organique et Analytique UMR-CNRS 6005, Université d'Orléans, B.P. 6759, F-45067 Orleans Cedex 2, France

^(d) Indena S.p.A., Viale Ortles 12, 20139 Milano, Italy.

^(*)Corresponding author: Brunelli Dario, Via La Masa 19, 20156 Milano, Italy, Tel: +39 02 39014239; Fax: +39 02 39014734; E-mail: brunelli@marionegri.it

ABSTRACT

Glucosinolates (GLs), natural compounds extracted from *Brassicaceae* and precursors of isothiocyanates (ITCs), have been studied in the last decades mostly due to their

chemopreventive activity and, more recently, for their potential use as novel
chemotherapeutics. The aim of the present study was to investigate the *in vitro* and *in vivo*
activity of glucomoringin (GMG), an uncommon member of the GLs family, and to compare
it with glucoraphanin (GRA), one of the most studied GL. We have evaluated the potency of
both compounds in inducing cell death, cell cycle perturbations, apoptosis, NF- κ B inhibition
and GST- π activity in human carcinoma cells with different GST- π contents as well as in
human multiple myeloma and leukaemia cell lines. GMG-derived ITC (GMG-ITC) showed to
be more effective compared to GRA-derived ITC (Sulforaphane), especially in inhibiting NF-
 κ B activity and inducing apoptosis through a caspase-dependent pathway; these effects were
more pronounced in myeloma cells, in which we could also observe a long lasting growth
inhibitory effect, probably due to NF- κ B inhibition, which is considered essential for
myeloma cell survival. Both GLs were able to induce cell death in the μ M range in all tested
cell lines but caused cell cycle perturbations only in myeloma cells; they were also able to
modulate the GST/GSH pathway by causing a 3-fold increase in GST- π activity in MCF7
cells. *In vivo* study showed that pure GMG-ITC was only slightly active in a carcinoma mice
model, whereas it had significant antitumoral activity in a myeloma model, causing little
toxicity.

KEYWORDS: isothiocyanate; glucosinolate; myeloma; NF- κ B; sulforaphane

1 INTRODUCTION

Vegetables are important sources of compounds with cancer chemopreventive activity [1,2]. Among them are isothiocyanates (ITCs), species generated in *Brassicaceae* such as broccoli, Brussels sprouts and cauliflower, and they have attracted a lot of research interest as modulators of tumor growth since the original observation by Sidransky's group [3]. In vegetables, ITCs are stored in the form of inactive precursors called glucosinolates (GLs) and can be released after tissue damage by enzymatic hydrolysis involving myrosinase (MYR, E.C. 1.2.1.147), a thioglucoside glucohydrolase that is physically separated from GLs under normal conditions [4,5]. As the intestinal microflora of mammals, including humans, possess myrosinase-like activity, GLs can also be converted into ITCs in the mammalian digestive tract [6,7]. ITCs have been reported to inhibit tumor growth in different preclinical *in vivo* studies [8-10]. Moreover, epidemiological studies have shown an inverse relationship between dietary consumption of *Brassicaceae* and risk of developing lung, breast and colon cancer [11-13]. ITCs have many effects through which they may exert their protective action against cancer progression: they can induce phase-2 drug metabolizing enzymes like glutathione-S-transferase (GST) and quinone-reductase (QR) [14-17] through a Nrf-2 pathway, cause cell cycle arrest and apoptosis [18-20] and inhibit phase-I drug metabolizing enzymes and NF-kB related genes [20-22]. Sulforaphane (4-methylsulfinylbutyl isothiocyanate) is an ITC which has been extensively studied in recent years, as it was found to possess cancer chemopreventive and chemotherapeutic properties in a variety of preclinical models [9,13,22]. Glucomoringin (GMG) (4(alpha-L-rhamnosyloxy)-benzyl isothiocyanate) is an atypical GL due to the presence of a second saccharide residue in the aglycon side chain which might confer biological properties on the GL scaffold which are distinctly different from those of other members of the family (Fig.1). In the light of the putative role of sulforaphane and other ITCs [8] in cancer management, we wanted to characterize potential cancer chemotherapeutic properties of GMG-ITC. The cytotoxicity, cell cycle phase

perturbation, GST activity modulation, NF- κ B regulation, apoptosis induction and caspase activation induced by myrosinase-activated GMG (MA-GMG) were investigated *in vitro* in various carcinoma, leukaemia and myeloma cell lines and compared with those of sulforaphane generated from glucoraphanin (MA-GRA). Finally, since the *in vitro* studies revealed a much greater potency of MA-GMG on myeloma cells compared to both leukemia and carcinoma cells, chemically purified GMG-ITC was also tested in a preliminary *in vivo* study comparing its anti-neoplastic activity in mice bearing either human myeloma or carcinoma in order to confirm the increased efficacy on myelomas and to address its potential as a novel chemotherapeutic.

2 MATERIALS AND METHODS

2.1 Isolation and purification of compounds

GMG and GRA were isolated respectively from *Moringa oleifera* L. (fam. *Moringaceae*) and *Brassica oleracea* L. (fam. *Brassicaceae*; var. *acephala*; subvar. *laciniata*) seeds. Both GLs were purified in two sequential steps, by anion exchange and size exclusion chromatography, according to previously reported methods [23,24]. Individual GLs were characterised by ^1H and ^{13}C NMR spectrometry and the purity was assayed by HPLC analysis of the desulfo-derivative according to the ISO 9167-1 method (EEC Regulation No 1864/90 Enclosure VIII. Offic. Eur. Commun. L170: 27-34) resulting about 99% based on peak area value, but about 90-92% on weight basis due to their high hygroscopic properties. The enzyme MYR was

isolated from seeds of *Sinapis alba* L. according to a reported method [25] with some modifications. The stock solution used in the present study had a specific activity of ~60 units/mg of soluble protein and was kept at 4°C after dilution in H₂O at 34 U/ml. One MYR unit was defined as the amount of enzyme able to hydrolyse 1 µmole/min of sinigrin at pH 6.5 and 37°C. the MYR solution was stored at 4°C in sterile distilled water until use. GLs were dissolved in H₂O at a concentration of 1 mM, and kept at -20°C. Just before use, the solutions were diluted in medium at the desired concentration.. In every treatment made 5 µl of Myr for every 1.5 ml of GLs solutions were added in order to produce the active ITCs. GMG-ITC was produced via MYR catalyzed hydrolysis of GMG, performed in 0.1 M phosphate buffer pH = 6.5 at 37°C. The total conversion of pure GMG into GMG-ITC was confirmed by HPLC analysis of the desulfo-derivative (EEC Regulation No 1864/90 Enclosure VIII. Offic. Eur. Commun. L170: 27-34), which allowed us to monitor the reduction until complete disappearance of GMG in the reaction mixture. Acetonitrile was then added to the mixture until the final concentration was 20% and GMG-ITC was purified by reverse-phase chromatography, which was performed using a HR 16/10 column packed with LiChrospher RP-C18 (MERCK), connected to a GradiFrac System (Pharmacia). After washing with acetonitrile 20%, elution was carried out with a gradient up to 60% acetonitrile. Fractions were collected and analysed using a Hewlett-Packard Model 1100 HPLC system with an Inertsil ODS3 column (250 x 3 mm, 5 mm). Chromatography was performed with 1 mL/min flow rate at 30°C by eluting with a linear gradient of water (A) and acetonitrile (B) from 30% B to 80 % in 20 min. Elution of GMG-ITC was detected by a diode array, monitoring the absorbance at 229 nm. Fractions containing GMG-ITC (peak purity > 99%) were collected, the solvent were removed by concentration in a rotary evaporator, and the final solution was freeze-dried. The GMG-ITC was characterized and unambiguously identified by ¹H- and ¹³C-NMR and mass spectrometry techniques.

2.2 Drugs, cells culture condition and experimental tumor models

The human ovarian cancer cell line A2780, the human NSCLC (non-small cell lung cancer) H460 WT and its sub-line H460 S5 were grown in RPMI 1640 medium (Cambrex, Bio Science, Verviers, Belgium) containing 10% fetal bovine serum (FBS) (Sigma-Aldrich Co. Ltd, UK), 1% (v/v) 200 mM L-glutamine (Cambrex). H460 S5 cell line was derived from the parental line transfected by calcium-phosphate method with pCDNA3 (Invitrogen, Carlsbad, Ca, USA), containing an insert coding for the antisense sequence of the GST- π protein; this line was maintained in selection by adding 5 μ l/ml of G418 (100 mg/ml). The human mammarian cancer cell lines MCF7 π and NEO were grown in DMEM medium (Cambrex) containing 10% fetal bovine serum (FBS), 1% (v/v) 200 mM L-glutamine, 1% Sodium Pyruvate 100 mM (Cambrex) and 1% MEM non essential amino acid solution 100x (Cambrex); both cell lines were maintained in selection by adding 5 μ l/ml of G418 (100 mg/ml). MCF7 π cell line was derived from wild type cells transfected with a plasmid containing an insert coding for the GST- π protein while MCF7 NEO cell line was transfected with an empty plasmid. RAW-NF κ B, a murine immortalized macrophage cell-line, stably transfected with the luciferase gene put under a promoter responsive only to NF κ B, was grown in RPMI-1640 medium with 10% inactivated FBS (HyClone, Utah) and 1% (v/v) L-glutamine (200 mM). The human myeloid myeloma cell line RPMI-8226 was maintained in RPMI-1640 medium with 10% inactivated FBS and 1% (v/v) L-glutamine (200 mM). The human myeloid leukaemia cell line HL60 was maintained in RPMI-1640 medium with 10% inactivated FBS and 1% (v/v) L-Glutamine (200 mM). All cell lines were kept at 37 °C in a

humidified 5% CO₂ atmosphere in T-25-cm² tissue culture flasks (IWAKI, Bibby Sterilin, Staffordshire, UK). All cell lines used are stable immortalized cancer cell lines and experiments were performed with cells not exceeding 30 passages. For *in vivo* studies 4 to 6-week-old female CD1 *nu/nu* mice (Charles River, Calco, Lecco, Italy) and 5-week old male SCID mice were used. Mice were maintained under specific pathogen-free conditions, and provided food and water *ad libitum*. Procedures involving animals and their care are conducted in conformity with the institutional guidelines that are in compliance with national (D.Ln.116, G.U., suppl. 40, 18 Febbraio 1992, Circolare No. 8, G.U., 14 Luglio 1994) and international laws and police (EEC Council Directive 86/609, OJ L 358, 1, Dec. 12, 1987; Guide for the use of laboratory animals, United State National Research Council, 1996). Human ovarian A2780 cancer cells (8*10⁶ cell/mouse) and human myeloma RPMI8226 cancer cells (30*10⁶ cell/mouse) were implanted s.c. into the flank of recipient mice. When tumor was palpable (mean tumor weight value for the groups was 100-150 mg for the RPMI8226 bearing mice and 50-100 mg for the A2780 bearing mice respectively), animals were divided randomly into test groups consisting of 6-8 mice each, according to *Geran et al.* Tumor growth was measured every two days using a calliper. GMG-ITC was dissolved in H₂O:Tween 5% and drug solutions were prepared every day before treatments; mice were treated i.p. daily, 5 days a week for 2-3 weeks with 20 mg/kg of GMG-ITC.

2.3 Flow cytometric DNA cell cycle analysis

Exponentially growing cells were treated for 24 hours with different concentration of myrosinase-activated-GLs. At the end of treatment and at different time intervals after drug-

washout the cells were counted by a Coulter Counter Channelyzer 256 (Beckman Coulter) and fixed in 70% cold ethanol and kept at 4°C. The cells were washed with cold PBS and stained with a 1 ml solution containing 5 µg/ml propidium iodide in PBS and 12.5 µl/ml RNase 1% in water overnight in the dark. Flow cytometric cell cycle analysis were performed on at least 20.000 cells by using FACS Calibur instrument (Becton Dickinson, Sunnyvale, CA, USA). Fluorescence pulses were detected using a laser beam at 488 nM and a band pass filter 620±35 nm, for red fluorescence, in combination with a dichroic mirror at 570 nm. [26]. Percentages of distribution of cells in the phases of the cell cycles were analyzed according to the method by Bertuzzi et al.[27]

2.4 Cell death

Apoptosis was evaluated by two different methods: TUNEL Assay and Caspase-3 activation. TUNEL assay was performed following this protocol: at the end of treatment, and at different time intervals after drug washout, the cells were fixed in 70% ethanol and kept at 4°C before staining. The fixed cells were washed in cold PBS and permeabilized with 0.25% Triton X-100 (Sigma) in PBS for 5 minutes in ice. After removing Triton X-100, cells were incubated in 50 µl of solution containing terminal-dUTP-transferase (TdT) and FITC-conjugated dUTP deoxynucleotides 1:1 in storage buffer (Boehringer Mannheim, Germany) for 90 min at 37 °C in the dark. Caspase-3 activation was assessed by fixing cells in 1% paraformaldehyde for 1 hour in ice and, subsequently, in 70% ethanol. Cells were washed in PBS and permeabilized for 10 minutes with 0.004% saponin in PBS supplemented with 0.5% BSA and 5 mM EDTA. After centrifugation cells were resuspended with 20 µl of anti-active caspase-3 direct PE-antibody (BD Biosciences, Pharmingen, Canada) for 1 hour in the dark. Flow cytometric

analysis were performed on at least 20.000 cells by using FACS Calibur instrument.

Fluorescence pulses were detected using a laser beam at 488 nM and a band pass filter

530±25 nm for FITC fluorescence and 585±45 nm for PE fluorescence.

2.5 Luciferase Assay

For this assay we used a commercial kit (E1500, Promega, Madison, WI, USA). Briefly, RAW-NFkB cells were plated in 6 wells Petri at 150000 cells/ml (2 ml/well) and 24 hours later were treated with different concentrations of myrosinase-activated-GLs. After 24 hours cells were washed with cold PBS and we added Passive Lysis Buffer (1X) for 10 minutes to lyse the membranes. The pellet was then collected, centrifuged, and supernatant kept at – 20°C. Proteins were quantified by a standard kit (BioRad, USA) and 20 µl were put in a round-bottom tube (Becton Dickinson, MA, USA). For every 25 µl of protein solution 50 µl of Luciferase Substrate were added and the samples were read with a Lumat LB 9057 (EG&G BERTHOLD) luminometer for 10 seconds.

2.6 NF-kB activity assay

This assay was performed using a commercial kit (EZ-DETECT NfκB p50 Transcription Factor Kit, PIERCE, Rockford, IL, USA) which, by using plates coated with specific NF-kB DNA consensus sequences to which only the active NF-kB complex can ligate, can minimize

nonspecific binding. Exponentially growing RPMI-8226 cells were treated for 24 h with different concentrations of myrosinase-activated-GLs. After the end of the treatment and 24 hours after drug washout cells were lysed using RIPA extraction buffer. The pellet was then collected, centrifuged, and supernatant kept at -20°C . Proteins were quantified by a standard kit (BioRad). Proteins were subsequently utilized to detect NF- κ B activity following manufacturer instructions.

2.7 GST- π activity assay

Exponentially growing MCF-7 cells were treated for 24 h with different concentration of myrosinase-activated-GLs. After treatment cells were scraped and resuspended in H_2O , sonicated and centrifuged and thereafter the supernatant was used to determine both protein concentration and GST activity. Proteins were quantified by a standard kit (BioRad, USA) and GST- π activity by monitoring the conjugation of glutathione with 1-chloro-2,4-dinitrobenzene (CDNB) following Habig protocol (Habig *et al.*, 1974). Briefly, 100 μl of proteins were put in solution with 100 μl GSH 10mM, 100 μl Phospate Buffer, 680 μl H_2O and 20 μl CDNB 50 mM; the increase in the absorbance at 340 nm generated by the conjugation reaction was then followed for 1 minute using a spectrophotometer (UVIKRON-860, Kontron Instrument) and the results expressed as percentage of control activity.

3 RESULTS

3.1 Growth inhibition and cell cycle effects

In preliminary studies exposure-efficacy conditions for MA-GMG and MA-GRA in various human carcinoma cell lines were optimised using the MTT assays (data not shown). The effects incremented by increasing the exposure time up for 24 h but only a modest increase was observed for 48 and 72 h exposures; 24 h treatment was, thus, considered as the optimal exposure time for the subsequent experiments. Due to the suggested role of the GST/GSH pathway in modulating ITCs cytotoxicity [12,14,16], ability of both MA-GMG and MA-GRA to induce cell death was subsequently studied using cell count assays in two pairs of isogenic carcinoma cell systems with a 2-fold (H460 WT / S5) or 25-fold (MCF7 π / NEO) difference in GST- π content. MA-GMG showed an IC₅₀ range of 18–29 μ M while MA-GRA was slightly less potent with a range of 19–30 μ M (Table 1). A small increase in potency of both compounds was present in the H460 S5 cell line compared to its WT counterpart but, on the other hand, no differences could be observed in the MCF7 model thus suggesting that this is probably not a major determinant in GCs cytotoxicity. To evaluate whether growth inhibition was associated with an alteration in cell cycle phase distribution, we also performed flow cytometric DNA cell cycle analysis on all the four cell lines. The ITCs did not cause any significant alteration in cell cycle phases distribution (data not shown).

3.2 Effects on GST- π activity

To better understand the potential role of the GST/GSH pathway in ITCs mechanism of action, we evaluated the effects of MA-GMG and MA-GRA on GST- π activity using the isogenic cell lines MCF7 NEO and MCF7 π : This model was preferred to the H460 one due to the increased differences in basal GST- π activity between the two cell lines thus permitting a more sensitive and accurate measurement of the effects. Enzymatic activity was measured 24 hour after ITCs treatment and results are shown in Fig.2. Both compounds induced GST- π activity in MCF7 NEO cells by 2.5 to 3.5-fold, whilst there was no significant induction in the MCF7 π line. Various studies [28,29] have related the growth-modulating activity of ITCs to their ability to deplete cellular GSH, thus rendering cells vulnerable to oxidative stress and apoptotic signalling. To explore whether the cytotoxic effect of MA-GMG and MA-GRA might have been caused by GSH depletion, we exposed MCF7 π and NEO cells to MA-GMG and MA-GRA after pre-treatment with the GSH-depleting agent BSO (buthionine sulfoximine). Pre-treatment with BSO failed to modify significantly the cytotoxic potential of either compound (results not shown).

3.3 Effects on NF-kB dependent gene expression

The transcription factor NF-kB is responsible for many cellular signalling pathways and changes in NF-kB-dependent gene regulation is often associated with tumorigenesis. In the light of the NFkB-inhibiting properties of sulforaphane [21,22] we studied the effects of MA-GMG and MA-GRA on NF-kB in RAW NF-kB cells. MA-GMG inhibited NF-kB activity, expressed as luciferase level, in a dose-dependent manner (Fig.3). Maximal inhibition (by

70%) was observed at 30 μ M. In contrast MA-GRA did not depress NF κ B activity by more than 30%. Since the survival of many human myeloma cell lines seems to be exquisitely sensitive towards alterations in NF- κ B related pathways [30-32], we decided to further investigate the ability of MA-GMG or MA-GRA to inhibit NF- κ B using the human multiple myeloma cell line RPMI-8226. Fig.4 shows NF- κ B activity at the end of treatment with MA-GMG or MA-GRA and 24 hours after drug washout. MA-GMG inhibited NF- κ B activity in these cells in a dose dependent manner at lower concentrations than those used in the experiments employing RAW NF- κ B cells described above. The inhibitory effect of MA-GMG was maintained up to 24 h after drug washout, whilst that of MA-GRA was reversed after treatment. The importance of NF- κ B inhibition in RPMI-8226 cell survival was further confirmed with the use of parthenolide and cymaropicrin, two previously reported NF- κ B inhibitors, which showed comparable results with those obtained with ITCs and a very strong correlation between NF- κ B inhibition and growth inhibition (supplementary materials)

3.4 Cell cycle perturbation and apoptosis induction on myelomas

Considering the NF- κ B inhibition observed in the RPMI-8226 cell line even at low drug concentrations, we decided to further investigate the growth inhibitory and cell cycle perturbation effects of both MA-GMG and MA-GRA using this model. Fig.5 shows that the growth inhibitory effect of both ITCs was 3-4 fold greater than those observed in carcinoma derived cell lines reaching an IC₅₀ of 6-7 μ M and, most noticeably, it was correlated with a strong cell cycle perturbation mainly due to a G₂M phase block (Table 2). To address if the observed increase in sensitivity was due to the different nature of the myeloma cells compared

to carcinoma-derived tumor cells, we performed the same experiments also on another myeloid-derived tumor which is typically quite sensitive to drug treatments, HL60; our results demonstrates that this was not the case since the IC₅₀s of 15-16 μ M obtained with both drug treatments were comparable to those obtained in solid tumor cells (Fig.6). It has been reported that GL-derived ITCs act as apoptotic inducers [18-20], thus we investigated this mechanism of cell death, once again, both on carcinoma-derived and myeloid-derived cell lines. After MA-GMG or MA-GRA exposure, H460 WT and H460 S5 cell lines showed no apoptosis induction (data not shown) and the same results were also obtained with HL60 cells (Fig.7, right upper panel) while, on the other hand, both compounds induced apoptosis in RPMI-8226 cells (Fig.7, left upper panel) and the percentage of apoptotic cells detected was higher after MA-GMG treatment. Apoptotic cells were already detectable after 6 hours exposure (data not shown). With the aim of understanding whether the apoptotic process was caspase-3 dependent, we also marked cells with an anti-caspase antibody (Fig.7, lower panel). The results showed a nearly perfect correlation between the percentages of apoptotic and caspase-3 activated cells for both the RPMI-8226 (lower left panel) and HL60 (lower right panel) suggesting that the caspase pathway is the main, if not the only, pathway involved in this apoptotic process.

3.5 GMG-ITC activity in experimental tumor mouse model

In order to evaluate its potential use as an antineoplastic agent against carcinomas or myelomas, GMG-ITC was administered to two different murine cancer models. In the first model, Swiss Ncr *nu/nu* mice bearing A2780 ovarian cancer were treated daily, 5 days a

week, for 2 weeks with i.p. injections of either 20 mg/kg GMG-ITC or an equivalent volume of vehicle solution. Treated mice showed a reduced tumor growth (Fig.8, upper panel), with the difference between the two groups becoming statistically significant starting from day 13, 3 days after the end of the treatment period. No toxicity was observed during the whole experimental period but, despite the reduced growth observed in treated mice, T/C values did not indicate a significant antitumoral activity with the best T/C value of 53.8 %. In the second model, SCID mice bearing RPMI-8226 myeloma received either GMG-ITC or vehicle solution following the same schedule used in the former experiment. Mice receiving GMG-ITC showed a significantly slower tumor growth rate compared to controls starting from day 8 (Fig.8, lower panel). Toxicity was not observed (Max BWL = 7,8 %) and T/C values demonstrated a statistically significant difference between the two groups with a best T/C of 33.9%. For this reason, treatment was continued into a 3rd week. At the end of the 3rd week GMG-ITC started to show toxicity with 2 out of 8 mice dying.

4 DISCUSSION

GL-derived ITCs have been intensively studied in the last years due to their chemopreventive effects and, more recently, various studies demonstrated their potential use as novel chemotherapeutics [9,13,22]. GMG is an uncommon member of the GLs family and presents a unique characteristic consisting in a second saccaridic residue in its side chain. This GLs is a typical secondary metabolite present in vegetables belonging to the genus *Moringaceae* that consists of 14 species, among which *M. oleifera* is the most widely distributed. *M. oleifera* is a multipurpose tree which grows in many tropical or equatorial regions. The medical value of

the seeds and other part of the plant have long been recognized in folk medicine [33]. The glycosylated ITC, resulting from myrosinase-hydrolysis of GMG, has been shown to exhibit a broad biological activity [33] and it was also shown to exert an effective antitumor activity [34]. GMG-ITC is a solid, odorless, and stable compound at room temperature that can be purified easily in high amounts differing from others natural bioactive ITCs which are liquid, volatile, with pungent odors and usually present at lower concentrations. What we presented in this study represent the first data on this molecule and our findings demonstrate its potential use as a novel chemotherapeutic compound, especially considering its overall increased potency compared to the most studied ITC, Sulforaphane. Our first experiments were aimed at determining the best time-exposure protocols and concentration range of activity of the two molecules in various human carcinoma cell lines, resulting in an optimal 24 hours schedule of treatment at μM concentrations. The cell cycle analysis showed that both ITCs are unable to induce detectable cell cycle perturbations while still being able to significantly inhibit cell growth suggesting that in those cell lines, probably, ITCs do not activate a specific cell cycle checkpoint but slow down the progress of cells through all phases of cell cycle. Various studies have demonstrated that ITCs are able to induce phase-2 drug metabolizing enzymes and, among them, Glutathione-S-Transferase (GST) [14-17] has always been considered of great importance for these compounds to exert their effects. We investigated the ability of MA-GMG and MA-GRA to modulate GST- π activity in two isogenic cell lines (MCF7 π and NEO) with a 25 fold relative difference in GST- π basal activity. Our results suggest that, despite the partial influence shown by ITCs on the GST/GSH system, their cytotoxic effects are not as closely related to this. Both compounds, infact, did not show a significant increase in their potency even when coupled with the GSH depleting agent BSO (data not shown) despite being able to induce a 2,5 to 3,5 fold increase in its activity in MCF7 NEO cells. The NF- κB pathway is often associated with tumorigenesis

when deregulated and, since it has been shown that ITCs can also modify the expression of various genes associated with inflammatory response [14-22], we decided to compare MA-GMG and MA-GRA effects on the expression of NF- κ B and NF- κ B dependant genes. Our experiments showed that both drugs were able to significantly downregulate NF- κ B activity with MA-GMG showing a good dose-responsiveness with a peak of 70 % inhibition at 30 μ M and MA-GRA being less potent with a 30 % inhibition peak. Due to the great importance of NF- κ B related pathway in myeloma cells survival [30-32], we subsequently tested both compounds also on the RPMI-8226 human multiple myeloma cell line; both drugs showed an increased inhibitory effect in these cells with 40 % inhibition already at 10 μ M. Most noticeably, MA-GMG effect lasted up to 24 hours after drug washout. In light of these results, we decided to perform also cell count assays and cell cycle analysis to better evaluate the potency of GL-derived ITCs on this type of malignant cells compared to carcinomas. Our experiments not only showed that both MA-GMG and MA-GRA were able to induce a stronger growth inhibitory effect and at lower doses (5-15 μ M) but also that both drugs were able to induce long lasting cell cycle perturbations mostly consisting in G₂M accumulation. To highlight if this greater potency was due to the different heritage of myeloid-derived tumors compared to carcinomas, we performed the same experiments on the HL60 leukemia cell line. The results obtained demonstrated that this was not the case since HL60 cells did not show an increased sensitivity to MA-GMG or MA-GRA treatments compared to carcinoma cells, with a comparable IC₅₀ of 15 μ M. We also report here that both ITCs are able to induce caspase-3 dependant apoptosis in multiple myeloma cells but not in other myeloid nor carcinoma cells (data not shown). Even in this case MA-GMG showed a stronger and longer lasting effect when compared to MA-GRA. To confirm our *in vitro* data we finally performed a preliminary *in vivo* test comparing the activity of the purified GMG-ITC in two different mice models bearing either a carcinoma or a myeloma. As expected, GMG-ITC showed little

activity in the carcinoma model reaching a best T/C value of 53,8 % while, on the contrary, it was able to statistically affect the tumor growth rate in the myeloma model reaching a best T/C of 33,9 % and maintaining a statistically significant activity for more than 14 days (from day 4th to day 18th). The mechanism of action of GL-derived ITCs still remains largely unknown but the results presented in this paper, showing an increased sensitivity of myeloma cells compared to carcinoma cells to ITC treatment both *in vitro* and *in vivo*, suggest that the inhibitory effects on NF-kB activity may play a key role in their activity considering that myelomas are known to strongly depend on NF-kB expression for their growth. Recently, the proteasome inhibitor Velcade was found effective on myelomas [35-37] and it was suggested that the reason for its specificity is linked to the reduced catabolism of IκB which, in turns, inhibit NF-kB activation. Multiple myeloma still remains one of the malignancies with the highest mortality and for this reason, despite new therapies with Velcade have improved the chances of survival for myeloma's patients, the need for new and improved drugs is still high. We envision the possibility that other drugs active on NF-kB inhibition, could have some potential for the treatment of myelomas and, in this respect, GL-derived ITCs could be possible candidates considering their relatively low toxicity. GMG-ITC seems to be a good candidate for further investigating ITCs potential in myeloma treatment since our results demonstrate that it is more potent than the commonly studied Sulforaphane and, in addition, it is easily extracted from the seeds of *M.oleifera* where it represents roughly 8-10 % of the whole weight, thus making GMG one of the most available and probably also the most economic GL to obtain and purify.

Acknowledgements

The generous contribution of the Italian Association for Cancer Research (AIRC) and Fondazione Mattioli to the Department of Oncology of Mario Negri Institute is greatly appreciated. This study was conducted with the financial support of Indena S.p.A.

Conflict of interest:

Carla Manzotti and Carlo Morazzoni are employees of Indena S.p.A. who supported the study

References

- [1] D'Incalci M, Steward WP, Gescher AJ. Use of cancer chemopreventive phytochemicals as antineoplastic agents. *Lancet Oncol.* 2005;6(11):899-904
- [2] D'Incalci M., Brunelli D., Marangon E., Simone M., Tavecchio M., Gescher A. and Mantovani R. Modulation of gene transcription by natural products - a viable anticancer strategy. *Curr Pharm Design* 2007;13(27):2744-2750
- [3] Sidransky H, Ito N, Verney E. Influence of alpha-naphthyl-isothiocyanate on liver tumorigenesis in rats ingesting ethionine and N-2-fluorenylacetamide. *J Natl Cancer Inst.* 1966;37(5):677-686.
- [4] Fenwick GR., Heaney RK., and Mullin WJ. Glucosinolates and their breakdown products in food and food plants. *Crit. Rev. Food Sci. Nutr.* 1983;18(2):123–201

- [5] Fahey JW., Zalcmann AT., and Talalay P. The chemical diversity and distribution of glucosinolates and isothiocyanates among plants. *Phytochemistry* 2001;56(1):5–51.
- [6] Shapiro TA, Fahey JW, Wade KL, Stephenson KK, Talalay P. Human metabolism and excretion of cancer chemoprotective glucosinolates and isothiocyanates of cruciferous vegetables. *Cancer Epidemiol Biomarkers Prev.* 1998;7(12):1091-1100
- [7] Getahun SM, Chung FL. Conversion of glucosinolates to isothiocyanates in humans after ingestion of cooked watercress. *Cancer Epidemiol Biomarkers Prev.* 1999;8(5):447-451
- [8] Zhang Y, Talalay P. Anticarcinogenic activities of organic isothiocyanates: chemistry and mechanisms. *Cancer Res.* 1994;54(7 Suppl):1976-1981.
- [9] Hecht SS. Inhibition of carcinogenesis by isothiocyanates. *Drug Metab. Rev.* 2000;32(3-4):395-411.
- [10] Conaway CC., Yang YM. and Chung FL. Isothiocyanates as cancer chemopreventive agents: their biological activities and metabolism in rodents and humans. *Curr. Drug Metab.* 2002;3(3):233–255.
- [11] Fowke JH, Chung FL, Jin F, Qi D, Cai Q, Conaway C, Cheng JR, Shu XO, Gao YT, Zheng W. Urinary isothiocyanate levels, brassica, and human breast cancer. *Cancer Res.* 2003;63(14):3980-6.
- [12] Zhao B, Seow A, Lee EJ, Poh WT, Teh M, Eng P, Wang YT, Tan WC, Yu MC, Lee HP. Dietary isothiocyanates, glutathione S-transferase -M1, -T1 polymorphisms and lung cancer risk among Chinese women in Singapore. *Cancer Epidemiol Biomarkers Prev.* 2001;10(10):1063-7
- [13] Conaway CC, Wang CX, Pittman B, Yang YM, Schwartz JE, Tian D, McIntee EJ, Hecht SS, Chung FL. Phenethyl isothiocyanate and sulforaphane and their N-acetylcysteine conjugates inhibit malignant progression of lung adenomas induced by tobacco carcinogens in A/J mice. *Cancer Res.* 2005;65(18):8548-8557.

- [14] Steinkellner H., Rabot S., Freywald C., Nobis E., Scharf G., Chabicovsky M., Knasmuller S. and Kassie F. Effects of cruciferous vegetables and their constituents on drug metabolizing enzymes involved in the bioactivation of DNA-reactive dietary carcinogens. *Mutat. Res.* 2001;480–481:285–297.
- [15] Talalay P. and Fahey JW. Phytochemicals from cruciferous plants protect against cancer by modulating carcinogen metabolism. *J. Nutr.* 2001;131(11 Suppl.):3027–3033.
- [16] Brooks JD., Paton VG. and Vidanes G. Potent induction of phase 2 enzymes in human prostate cells by sulforaphane. *Cancer Epidemiol. Biomarkers. Prev.* 2001;10(9): 949–954.
- [17] McWalter GK, Higgins LG, McLellan LI, Henderson CJ, Song L, Thornalley PJ, Itoh K, Yamamoto M, Hayes JD. Transcription factor Nrf2 is essential for induction of NAD(P)H:quinone oxidoreductase 1, glutathione S-transferases, and glutamate cysteine ligase by broccoli seeds and isothiocyanates. *J. Nutr.* 2004;134(12 Suppl):3499-3506.
- [18] Fimognari C, Nusse M, Cesari R, Iori R, Cantelli-Forti G, Hrelia P. Growth inhibition, cell-cycle arrest and apoptosis in human T-cell leukemia by the isothiocyanate sulforaphane. *Carcinogenesis.* 2002;23(4):581-6.
- [19] Bonnesen C., Eggleston IM. and Hayes JD. Dietary indoles and isothiocyanates that are generated from cruciferous vegetables can both stimulate apoptosis and confer protection against DNA damage in human colon cell lines. *Cancer Res.* 2001;61(16):6120–6130.
- [20] Srivastava SK, Singh SV. Cell cycle arrest, apoptosis induction and inhibition of nuclear factor kappa B activation in anti-proliferative activity of benzyl isothiocyanate against human pancreatic cancer cells *Carcinogenesis* 2004;25(9):1701-9
- [21] Xu C, Shen G, Chen C, Gelinas C, Kong AN. Suppression of NF-kappaB and NF-kappaB-regulated gene expression by sulforaphane and PEITC through IkappaBalpha, IKK pathway in human prostate cancer PC-3 cells. *Oncogene.* 2005;24(28):4486-4495.

- [22] Heiss E, Herhaus C, Klimo K, Bartsch H, Gerhauser C. Nuclear factor kappa B is a molecular target for sulforaphane-mediated anti-inflammatory mechanisms. *J. Biol. Chem.* 2001;276(34):32008-32015
- [23] Barillari J, Gueyrard D, Rollin P, Iori R. Barbarea verna as a source of 2-phenylethyl glucosinolate, precursor of cancer chemopreventive phenylethyl isothiocyanate. *Fitoterapia* 2001;72(7):760-4.
- [24] Barillari J, Canistro D, Paolini M, Ferroni F, Pedulli GF, Iori R, Valgimigli L. Direct antioxidant activity of purified glucoerucin, the dietary secondary metabolite contained in rocket (*Eruca sativa* Mill.) seeds and sprouts. *J. Agric. Food. Chem.* 2005;53(7):2475-2482.
- [25] Pessina A, Thomas RM, Palmieri S, Luisi PL. An improved method for the purification of myrosinase and its physicochemical characterization. *Arch. Biochem. Biophys.* 1990;280(2):383-9.
- [26] Simone M, Erba E, Damia G, Vikhanskaya F, Di Francesco AM, Riccardi R, Bailly C, Cuevas C, Fernandez Sousa-Faro JM, D'Incalci M. Variolin B and its derivate deoxy-variolin B: new marine natural compounds with cyclin-dependent kinase inhibitor activity. *Eur. J. Cancer* 2005;41(15):2366-2377.
- [27] Bertuzzi A, Gandolfi A, Germani A, Spanò M, Starace G, Vitelli R. Analysis of DNA synthesis rate of cultured cells from flow cytometric data. *Cytometry.* 1984 Nov;5(6):619-628
- [28] Zhang Y. Role of glutathione in the accumulation of anticarcinogenic isothiocyanates and their glutathione conjugates by murine hepatoma cells. *Carcinogenesis.* 2000;21(6):1175-1182.
- [29] Zhang Y. and Talalay P. Mechanism of differential potencies of isothiocyanates as inducers of anticarcinogenic Phase 2 enzymes. *Cancer Res.* 1998;58(20):4632–9.
- [30] Ito K, Nakazato T, Xian MJ, Yamada T, Hozumi N, Murakami A, Ohigashi H, Ikeda Y, Kizaki M. 1'-acetoxychavicol acetate is a novel nuclear factor kappaB inhibitor with

significant activity against multiple myeloma in vitro and in vivo. *Cancer Res.*

2005;65(10):4417-4424.

[31] Yinjun L, Jie J, Yungui W. Triptolide inhibits transcription factor NF-kappaB and

induces apoptosis of multiple myeloma cells. *Leuk. Res.* 2005;29(1):99-105.

[32] Feinman R, Koury J, Thames M, Barlogie B, Epstein J, Siegel DS. Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. *Blood.*

1999;93(9):3044-3052.

[33] Anwar F., Latif S., Ashraf M., Gilani A.H. *Moringa oleifera*: A food plant with multiple Medicinal Uses. *Phytother. Res.* 2007;21(1):17-25

[34] Guevara AP., Vargas C., Sakurai H., Fujiwara Y., Hashimoto K., Maoka T., Kozuka M., Ito Y., Tokuda H., Nishino H. An antitumor promoter from *Moringa oleifera* *Mutat. Res.* 1999;440(2):181-8.

[35] Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC The Proteasome Inhibitor PS-341 Inhibits Growth, Induces Apoptosis, and Overcomes Drug Resistance in Human Multiple Myeloma Cells *Cancer Res.* 2001;61(7):3071-6

[36] LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, Neuberg D, Goloubeva O, Pien CS, Adams J, Gupta D, Richardson PG, Munshi NC, Anderson KC. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. *Cancer Res.* 2002;62(17):4996-5000.

[37] Altun M, Galaray PJ, Shringarpure R, Hideshima T, LeBlanc R, Anderson KC, Ploegh HL, Kessler BM. Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells. *Cancer Res.* 2005;65(17):7896-7901

Figure Captions

Fig.1: Chemical structures of Glucosinolates and GMG and GRA side chains.

Fig.2: GST- π activity in MCF7 π (white columns) and MCF7 NEO (black columns) cells evaluated after 24 hours MA-GMG or MA-GRA treatment. Results are shown as percentage of relative controls. Error bars represent the standard deviation. Statistical analysis: *:p<0,01 **:p<0,005 ***:p<0,001 compared with untreated controls.

Fig.3: NF-kB-dependent luciferase expression in RAW NF-kB after 24 hours treatment with MA-GMG (black columns) or MA-GRA (white columns). Data shown are mean values of 3 experiments each consisting of 3 replicates. Error bars represent the standard deviation. Statistical analysis: *:p<0,01 **:p<0,005 ***:p<0,001 compared with untreated controls. #:p<0,01 ##:p<0,005 ###:p<0,01 compared with MA-GMG treatments.

Fig.4: NF-kB activity in RPMI-8226 cell line cell line evaluated after 24 hours treatment with MA-GMG or MA-GRA and 24 hours after drug washout. Data shown are mean values of 2 experiments each consisting of 3 replicates. Error bars represent the standard deviation. Statistical analysis: *:p<0,01 **:p<0,005 ***:p<0,001 compared with untreated controls. #:p<0,01 ##:p<0,005 ###:p<0,01 compared with MA-GMG treatments.

Fig.5: Growth inhibitory effects (right) and cell cycle phase perturbations (left) induced on RPMI-8226 cell treated for 24 hours with 0 (—*), 5 (—●—), 7,5 (—■—), 10 (—▲—) or 15 μ M (—○—) of MA-GMG or MA-GRA. Error bars represent the standard deviation. IC50 values were calculated 48 hours after drug washout. Statistical analysis: *:p<0,01 **:p<0,005 ***:p<0,001 compared with untreated controls.

Fig.6: Growth inhibition induced on HL60 cell by 24 hours treatment with 10 (—■—), 20 (—▲—) and 30 μ M (—●—) MA-GMG or MA-GRA. IC50 values were calculated 48 hours after drug

washout. Error bars represent the standard deviation. Statistical analysis: *:p<0,01 **:p<0,005
***:p<0,001 compared with untreated controls.

Fig.7: Detection of apoptosis (upper panel): RPMI-8226 (left) and HL60 (right) cells were treated for 24 hours with 10 μ M of MA-GMG or MA-GRA. The biparametric TdT-d-UTP / Forward scatter flow cytometric analysis were performed after 24 hours treatments and 24, 48 and 72 hours after drug-washout. The percentage of apoptotic cells are also reported.

Experiments were repeated three times with comparable results.

Detection of active caspase-3 (lower panel): RPMI-8226 (left) and HL60 (right) cells were treated for 24 hours with 10 μ M of MA-GMG or MA-GRA. The biparametric caspase-3 /Forward scatter flow cytometric analysis were performed after 24 hours treatment and 24, 48 and 72 hours after drug-washout. The percentage of caspase-3 positive cells are also reported.

Experiments were repeated three times with comparable results.

Fig.8: Antitumoral activity of GMG-ITC on Swiss Ncr *nu/nu* mice bearing A2780 ovarian cancer (upper panel) or SCID mice bearing RPMI-8226 myeloma cancer (lower panel). Mice were treated with 20 mg/kg GMG-ITC i.p. once a day for 2 (*nu/nu* mice) or 3 (NUDE mice) weeks, 5 days a week. Result are shown as tumor weight of control (continuous line) and treated (crossed line) mice. Error bars represent the standard error. *: p<0,05 **: p<0,01 compared to control.

CELL LINE	CELL COUNT IC50 (μ M)	
	<i>MA-GMG</i>	<i>MA-GRA</i>
H460 WT	29,07 +/- 0,76	29,35 +/- 0,49
H460 S5	18,50 +/- 6,65	19,10 +/- 0,92
MCF7 π	21,08 +/- 5,67	27,33 +/- 3,85
MCF7 NEO	19,76 +/- 4,38	25,59 +/- 4,21

Table 1: IC50 values on different cell lines after 24 hours treatments with different concentrations of MA-GM or MA-GRA; IC50 values were calculated 48 hours after drug washout. Data are mean values of at least 3 experiments each consisting of 3 replicates.

	CTRL	GMG5	GMG7.5	GMG 10	GMG 15	GRA 5	GRA 7.5	GRA 10	GRA 15	
% G1	30	20	23	30	32	20	20	21	19	24hT
% S	53	59	40	28	29	54	53	54	56	
% G2M	17	21	36	42	39	26	27	25	25	
% G1	33	20	18	19	25	21	20	20	10	24hR
% S	51	60	68	71	64	61	60	51	54	
% G2M	16	20	14	10	11	18	20	29	36	
% G1	30	26	24	26	40	25	25	25	19	48hR
% S	53	48	63	56	51	57	54	56	61	
% G2M	17	16	13	18	9	18	21	19	20	
% G1	34	22	22	24	25	23	24	27	26	72hR
% S	50	58	59	57	57	59	57	52	51	
% G2M	16	20	19	19	18	18	19	21	23	

Table 2: Percentage of cells in the various phases of the cell cycle after 24 hours treatment with different concentrations of MA-GMG or MA-GRA and 24, 48 and 72 hours after drug washout.

Glucosinolates

Glucomoringin (GMG)

Glucoraphanin (GRA)

Figure2

Figure3

Figure4

Figure5

Figure6

Figure8

Day	T/C %
0	100
2	71,6
4	75,2
7	62,3
9	65,2
11	53,8
14	57,9
16	57,8
18	56,8
21	62,3

Day	T/C %
0	100
2	78,2
4	47,2
7	53,3
9	45,5
11	39,9
14	34,8
16	33,9
18	40,2
21	50,8

additional material

Supplementary Material: NF-kB inhibition (black bars) and growth inhibition (white bars) on RPMI-8226 cells after 24 hours treatment (24hT) with different concentrations of Parthenolide (left panel) or Cynaropicrin (right panel) and 24 hours after drug removal (24hR) . Error bars represent the standard deviation.